Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
Public ClinicalTrials.gov record NCT02104388. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared With Placebo to Assess Safety and Efficacy of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients With Moderate to Severe Corneal Epithelial Disorders
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to determine if SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
Study identification
- NCT ID
- NCT02104388
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 69 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 8, 2014 (Actual)
- Primary completion
- Aug 4, 2015 (Actual)
- Completion
- Aug 4, 2015 (Actual)
- Last update posted
- Mar 29, 2021
2014 – 2015
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Senju Investigational Site | Little Rock | Arkansas | 72205 | — |
| Senju Investigational Site | Glendale | California | 91206 | — |
| Senju Investigational Site | Glendora | California | 91741 | — |
| Senju Investigational Site | Huntington Beach | California | 92647 | — |
| Senju Investigational Site | Lancaster | California | 93534 | — |
| Senju Investigational Site | Newport Beach | California | 92663 | — |
| Senju Investigational Site | Pasadena | California | 91107 | — |
| Senju Investigational Site | Petaluma | California | 94954 | — |
| Senju Investigational Site | Santa Maria | California | 93454 | — |
| Senju Investigational Site | Hoffman Estates | Illinois | 60169 | — |
| Senju Investigational site | Edgewood | Kentucky | 41017 | — |
| Senju Investigational Site | Kansas City | Missouri | 64111 | — |
| Senju Investigational Site | Palisades Park | New Jersey | 07650 | — |
| Senju Investiational Site | Rochester | New York | 14642 | — |
| Senju Investigational Site | High Point | North Carolina | 27262 | — |
| Senju Investigational Site | Rapid City | South Dakota | 57701 | — |
| Senju Investigational Site | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02104388, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 29, 2021 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02104388 live on ClinicalTrials.gov.